• AAPL 170.65
  • TSLA 169.13
  • AMZN 177.94
  • MSFT 413.25
  • INTC 32.09
  • EURUSD 1.0722
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. AKBA.NASDAQ

Akebia Ther (AKBA NASDAQ) stock market data APIs

$1.35 0.02(1.5%) as of April 25, 2024

Akebia Ther Financial Data Overview

1.33
1.35
-
1.35
1.31
0.7801-2.48
287 M
209 M
195 M
0.0032
0.84
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'AKBA',
Type: 'Common Stock',
Name: 'Akebia Ther',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1517022',
EmployerIdNumber: '20-8756903',
FiscalYearEnd: 'December',
IPODate: '2014-03-20',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Akebia Ther Fundamental Data is available in our Financial Data APIs

  • Net Revenue 195 M
  • EBITDA -6 868 000
  • Earnings Per Share -0.28
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Akebia Ther Earnings via APIs

  • Latest Release 2024-03-28
  • EPS/Forecast -0.04

Get Akebia Ther End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Akebia Ther latest news via APIs

Akebia Secures $55 Million Term Loan Financing

Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical comp...

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Do you have any questions?
support@eodhistoricaldata.com